Enhanced carbonyl stress in a subpopulation of schizophrenia

Archives of General Psychiatry

Volumn 67, Issue 6, 2010, Pages 589-597

  Arai, Makoto ^a   Yuzawa, Hiroko ^b   Nohara, Izumi ^a   Ohnishi, Tetsuo ^c   Obata, Nanako ^a   Iwayama, Yoshimi ^c   Haga, Seiichi ^a   Toyota, Tomoko ^c   Ujike, Hiroshi ^d   Arai, Mayumi ^a   Ichikawa, Tomoe ^a   Nishida, Atsushi ^a   Tanaka, Yoko ^a   Furukawa, Aizo ^a   Aikawa, Yuuzou ^e   Kuroda, Osamu ^e   Niizato, Kazuhiro ^e   Izawa, Ryosuke ^e   Nakamura, Kazuhiko ^f   Mori, Norio ^f   Matsuzawa, Daisuke ^g   Hashimoto, Kenji ^h   Iyo, Masaomi ^g   Sora, Ichiro ⁱ   Matsushita, Masaaki ^e   Okazaki, Yuji ^e   Yoshikawa, Takeo ^c,j   Miyata, Toshio ^b,i   Itokawa, Masanari ^a,c,e,j   more..

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h CHIBA UNIVERSITY   (Japan)

ⁱ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBONYL DERIVATIVE; DIAZEPAM; HALOPERIDOL; HYPNOTIC AGENT; LACTOYLGLUTATHIONE LYASE; NITRAZEPAM; PENTOSIDINE; PYRIDOXINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHEMICAL ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVITY; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SCHIZOPHRENIA; VITAMIN BLOOD LEVEL; WESTERN BLOTTING;

ARGININE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LACTOYLGLUTATHIONE LYASE; LYSINE; MALE; MIDDLE AGED; OXIDATIVE STRESS; SCHIZOPHRENIA; VITAMIN B 6;

EID: 77953304746     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2010.62     Document Type: Article

References (52)

1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60(12):1187-1192.
2. Sullivan PF. The genetics of schizophrenia. PLoS Med. 2005;2(7):e212.
3. Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem. 2000;267(16):4904-4911.
4. Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, Matthey ML, Parnas J, Preisig M, Saraga M, Solida A, Timm S, Wang AG, Werge T, Cuénod M, Do KQ. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet. 2006;79(3):586-592.
5. Young J, McKinney SB, Ross BM, Wahle KW, Boyle SP. Biomarkers of oxidative stress in schizophrenic and control subjects. Prostaglandins Leukot Essent Fatty Acids. 2007;76(2):73-85. (Pubitemid 46217226)
6. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008; 11(6):851-876.
7. Kikuchi S, Shinpo K, Takeuchi M, Yamagishi S, Makita Z, Sasaki N, Tashiro K. Glycation: a sweet tempter for neuronal death. Brain Res Brain Res Rev. 2003; 41(2-3):306-323.
8. Thornalley PJ. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J. 1990;269(1):1-11.
9. Thornalley PJ. Glyoxalase I: structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans. 2003;31(Pt 6):1343-1348.
10. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in non-enzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int. 1999;55(2):389-399.
11. Thornalley PJ. The glyoxalase system in health and disease. Mol Aspects Med. 1993;14(4):287-371.
12. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry CP Jr, Liu L, Bresnahan M, Susser ES. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry. 2007;64(1):31-39. (Pubitemid 46041736)
13. Frankenburg FR. The role of one-carbon metabolism in schizophrenia and depression. Harv Rev Psychiatry. 2007;15(4):146-160.
14. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review.AmJ Epidemiol. 2007;165(1):1-13. (Pubitemid 46026203)
15. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuénod M, Do KQ. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A. 2007;104(42):16621-16626.
16. Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1289-1296.
17. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60(3):265-269.
18. Saadat M, Mobayen F, Farrashbandi H. Genetic polymorphism of glutathione S-transferase T1: a candidate genetic modifier of individual susceptibility to schizophrenia. Psychiatry Res. 2007;153(1):87-91. (Pubitemid 47374820)
19. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22(1-2):83-93. (Pubitemid 41831607)
20. Kirk RL, Theophilus J, Whitehouse S, Court J, Zimmet P. Genetic susceptibility to diabetes mellitus: the distribution of properdin factor B (Bf ) and glyoxalase (GLO) phenotypes. Diabetes. 1979;28(10):949-951. (Pubitemid 10250239)
21. Miyata T, van Ypersele de Strihou C, Imasawa T, Yoshino A, Ueda Y, Ogura H, Kominami K, Onogi H, Inagi R, Nangaku M, Kurokawa K. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int. 2001;60(6):2351-2359.
22. Fujimoto M, Uchida S, Watanuki T, Wakabayashi Y, Otsuki K, Matsubara T, Suetsugi M, Funato H, Watanabe Y. Reduced expression of glyoxalase-1 mRNA in mood disorder patients. Neurosci Lett. 2008;438(2):196-199.
23. Junaid MA, Kowal D, Barua M, Pullarkat PS, Sklower Brooks S, Pullarkat RK. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet A. 2004;131(1):11-17. (Pubitemid 39434789)
24. Sacco R, Papaleo V, Hager J, Rousseau F, Moessner R, Militerni R, Bravaccio C, Trillo S, Schneider C, Melmed R, Elia M, Curatolo P, Manzi B, Pascucci T, Puglisi- Allegra S, Reichelt KL, Persico AM. Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1. BMC Med Genet. 2007;8:11.
25. Politi P, Minoretti P, Falcone C, Martinelli V, Emanuele E. Association analysis of the functional Ala111Glu polymorphism of the glyoxalase I gene in panic disorder. Neurosci Lett. 2006;396(2):163-166. (Pubitemid 43276433)
26. Ledig M, Doffoel M, Ziessel M, Kopp P, Charrault A, Tongio MM, Mayer S, Bockel R, Mandel P. Frequencies of glyoxalase I phenotypes as biological markers in chronic alcoholism. Alcohol. 1986;3(1):11-14. (Pubitemid 16143332)
27. Ditzen C, Jastorff AM, Kessler MS, Bunck M, Teplytska L, Erhardt A, Krömer SA, Varadarajulu J, Targosz BS, Sayan-Ayata EF, Holsboer F, Landgraf R, Turck CW. Protein biomarkers in a mouse model of extremes in trait anxiety. Mol Cell Proteomics. 2006;5(10):1914-1920.
28. Hovatta I, Tennant RS, Helton R, Marr RA, Singer O, Redwine JM, Ellison JA, Schadt EE, Verma IM, Lockhart DJ, Barlow C. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature. 2005;438(7068):662-666. (Pubitemid 41740575)
29. Krömer SA, Kessler MS, Milfay D, Birg IN, Bunck M, Czibere L, Panhuysen M, Pütz B, Deussing JM, Holsboer F, Landgraf R, Turck CW. Identification of glyoxalase- I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci. 2005;25(17):4375-4384.
30. Arolt V, Lencer R, Nolte A, Müller-Myhsok B, Purmann S, Schürmann M, Leutelt J, Pinnow M, Schwinger E. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease. Am J Med Genet. 1996;67 (6):564-579.
31. Brzustowicz LM, Honer WG, Chow EW, Hogan J, Hodgkinson K, Bassett AS. Use of a quantitative trait to map a locus associated with severity of positive symptoms in familial schizophrenia to chromosome 6p. Am J Hum Genet. 1997; 61(6):1388-1396. (Pubitemid 28046916)
32. Nurnberger JI Jr, Foroud T. Chromosome 6 workshop report. Am J Med Genet. 1999;88(3):233-238.
33. Turner WJ. Genetic markers for schizotaxia. Biol Psychiatry. 1979;14(1):177-206.
34. Arai M, Yamada K, Toyota T, Obata N, Haga S, Yoshida Y, Nakamura K, Minabe Y, Ujike H, Sora I, Ikeda K, Mori N, Yoshikawa T, Itokawa M. Association between polymorphisms in the promoter region of the sialyltransferase 8B (SIAT8B) gene and schizophrenia. Biol Psychiatry. 2006;59(7):652-659.
35. Hattori E, Nakajima M, Yamada K, Iwayama Y, Toyota T, Saitou N, Yoshikawa T. Variable number of tandem repeat polymorphisms of DRD4: re-evaluation of selection hypothesis and analysis of association with schizophrenia. Eur J Hum Genet. 2009;17(6):793-801.
36. Ide M, Muratake T, Yamada K, Iwayama-Shigeno Y, Iwamoto K, Takao H, Toyota T, Kaneko N, Minabe Y, Nakamura K, Kato T, Mori N, Asada T, Someya T, Yoshikawa T. Genetic and expression analyses of FZD3 in schizophrenia. Biol Psychiatry. 2004;56(6):462-465.
37. Toyota T, Yoshitsugu K, Ebihara M, Yamada K, Ohba H, Fukasawa M, Minabe Y, Nakamura K, Sekine Y, Takei N, Suzuki K, Itokawa M, Meerabux JM, Iwayama- Shigeno Y, Tomaru Y, Shimizu H, Hattori E, Mori N, Yoshikawa T. Association between schizophrenia with ocular misalignment and polyalanine length variation in PMX2B. Hum Mol Genet. 2004;13(5):551-561.
38. Yamada K, Gerber DJ, Iwayama Y, Ohnishi T, Ohba H, Toyota T, Aruga J, Minabe Y, Tonegawa S, Yoshikawa T. Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proc Natl Acad Sci U S A. 2007;104 (8):2815-2820.
39. Arinami T, Ohtsuki T, Ishiguro H, Ujike H, Tanaka Y, Morita Y, Mineta M, Takeichi M, Yamada S, Imamura A, Ohara K, Shibuya H, Ohara K, Suzuki Y, Muratake T, Kaneko N, Someya T, Inada T, Yoshikawa T, Toyota T, Yamada K, Kojima T, Takahashi S, Osamu O, Shinkai T, Nakamura M, Fukuzako H, Hashiguchi T, Niwa SI, Ueno T, Tachikawa H, Hori T, Asada T, Nanko S, Kunugi H, Hashimoto R, Ozaki N, Iwata N, Harano M, Arai H, Ohnuma T, Kusumi I, Koyama T, Yoneda H, Fukumaki Y, Shibata H, Kaneko S, Higuchi H, Yasui-Furukori N, Numachi Y, Itokawa M, Okazaki Y; Japanese Schizophrenia Sib-Pair Linkage Group. Genomewide highdensity SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet. 2005;77(6):937-944.
40. McLellan AC, Thornalley PJ. Glyoxalase activity in human red blood cells fractioned by age. Mech Ageing Dev. 1989;48(1):63-71. (Pubitemid 19120417)
41. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci U S A. 1996;93(6):2353-2358. (Pubitemid 26104354)
42. Bisp MR, Bor MV, Heinsvig EM, Kall MA, Nexø E. Determination of vitamin B6 vitamers and pyridoxic acid in plasma: development and evaluation of a high-performance liquid chromatographic assay. Anal Biochem. 2002;305(1): 82-89. (Pubitemid 34575827)
43. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function- measured and estimated glomerular filtration rate. N Engl J Med. 2006;354 (23):2473-2483. (Pubitemid 43855050)
44. Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C, Kurokawa K. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol. 1998;9(9):1681-1688.
45. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, Maeda K. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol. 1996;7(8): 1198-1206. (Pubitemid 27468273)
46. Koyama K, Usami T, Takeuchi O, Morozumi K, Kimura G. Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. Nephrol Dial Transplant. 2002;17(5):916-922. (Pubitemid 34521148)
47. Rhodes J. Covalent chemical events in immune induction: fundamental and therapeutic aspects. Immunol Today. 1996;17(9):436-441. (Pubitemid 26278370)
48. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269(13): 9889-9897. (Pubitemid 24196599)
49. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K. Angiotensin II receptor antagonists and angiotensin- converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002; 13(10):2478-2487.
50. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun. 1996;220(1):113-119.
51. Izuhara Y, Nangaku M, Takizawa S, Takahashi S, Shao J, Oishi H, Kobayashi H, van Ypersele de Strihou C, Miyata T. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant. 2008;23(2):497-509.
52. Vander Jagt DL, Hunsaker LA. Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem Biol Interact. 2003;143-144: 341-351.